SCIENTIFIC ARTICLE

Effect of low dose dexmedetomidine premedication on propofol consumption in geriatric end stage renal disease patients

Pinar Ergenoglu*, Sule Akin, Cagla Bali, Hatice Evren Eker, Oya Yalcin Cok, Anis Aribogan

Baskent University School of Medicine, Anesthesiology and Reanimation Department, Adana, Turkey

Received 17 September 2014; accepted 11 November 2014
Available online 2 May 2015

KEYWORDS
Geriatric patient; End stage renal disease; Dexmedetomidine; Propofol

Abstract
Background and objective: Sedation in dialysis dependent end-stage renal disease patients requires caution as a result of performing high doses of sedatives and its complications. Multidrug sedation regimens might be superior and advantage on lesser drug consumption and by the way adverse events which occur easily in end-stage renal disease patients. We evaluated the effects of dexmedetomidine premedication on propofol consumption, sedation levels with Observer’s Assessment of Alertness and Sedation scores and the bispectral index and the hemodynamic changes, potential side effects in geriatric patients with end-stage renal disease who underwent hip fracture surgery under spinal anesthesia.

Method: In this randomized, controlled, double-blind study 60 elderly patients (age ≥ 65 years) with end-stage renal disease and hip fracture scheduled for anterograde femoral intramedullary nailing were assigned to groups that received either intravenous saline infusion (Group C) or dexmedetomidine 0.5 μg/kg/10 min infusion for premedication (Group D). All the patients received propofol infusion after the induction of the spinal anesthesia.

Results: Total propofol consumption, propofol dose required for targeted sedation levels according to Observer’s Assessment of Alertness and Sedation scores and bispectral index levels, recovery times were significantly lower in Group D (p < 0.001). The time to reach to Observer’s Assessment of Alertness and Sedation score 4 and to achieve bispectral index ≤ 80 was significantly lower in Group C compared with Group D (p < 0.001). Adverse events were similar in both groups.

Conclusion: Dexmedetomidine premedication lowers intraoperative propofol consumption to maintain targeted level of sedation. Therefore low dose dexmedetomidine premedication in addition to propofol infusion might be an alternative in geriatric patients with end-stage renal disease for sedation.

© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
PALAVRAS-CHAVE
Paciente geriátrico; Doença renal em estágio terminal; Dexmedetomidina; Propofol

Efeito da pré-medicação com dose baixa de dexmedetomidina sobre o consumo de propofol em pacientes geriátricos com doença renal em estágio terminal

Resumo
Justificativa e objetivo: A sedação em paciente dependente de diálise com doença renal em estágio terminal (DRET) requer cautela como resultado da administração de altas doses de sedativos e suas complicações. Os regimes de sedação com múltiplas drogas podem ser superiores e vantajosos em relação ao consumo menor de drogas e aos eventos adversos que ocorrem facilmente em pacientes com DEET. Avaliamos os efeitos da pré-medicación com dexmedetomidina sobre o consumo de propofol, os níveis de sedação com os escores da Observer’s Assessment of Alertness and Sedation (OAA/S) e do índice bispectral (BIS), as alterações hemodinâmicas e os potenciais efeitos colaterais em pacientes geriátricos com DRET submetidos à cirurgia para fractura de quadril sob raquianestesia.

Método: Neste estudo randômico, controlado e duplo-cego, 60 pacientes idosos (idade ≥ 65 anos), com DRET e fratura de quadril, agendados para fixação intramedular de haste femoral antegrada foram designados para grupos para receberem infusão intravenosa de solução salina (Grupo C) ou pré-medicación com infusão de 0,5 mg kg/10 min de dexmedetomidina (DEX) (Grupo D). Todos os pacientes receberam infusão de propofol após a indução da raquianestesia.

Resultados: O consumo total de propofol, a dose de propofol necessária para os níveis-alvo de sedação de acordo com os escores da OAA/S, os valores do BIS e os tempos de recuperação foram significativamente menores no Grupo D (p < 0,001). O tempo para atingir o escore 4 na OAA/S e valores BIS ≤ 80 foi significativamente inferior no Grupo C em comparação com o Grupo D (p < 0,001). Os eventos adversos foram semelhantes em ambos os grupos.

Conclusão: A pré-medicación com dexmedetomidina reduz o consumo de propofol no intraoperatorário para manter o nível-alvo de sedação. Portanto, a pré-medicación com DEX em dose baixa em combinação com infusão de propofol pode ser uma alternativa para sedação em pacientes geriátricos com DRET.

© 2015 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. Todos os direitos reservados.

Introduction

The incidence of end stage renal disease and dialysis population in the elderly continues to increase universally. Hip fractures are also major problem and the anesthesia technique should be planned in detail due to potential alterations in volume distribution, protein binding, and drug metabolism and excretion. In an ideal anesthesia regime, the most important parameters are providing hemodynamic stability with optimal fluid and electrolyte balance, using drugs with a lower metabolism, shorter half-life and non-renal clearance, targeting early recovery and return of cognitive and psychomotor functions.

Neuraxial techniques such as single spinal injection is frequently performed for the intraoperative anesthesia management of patients with chronic renal failure. Co-administration of spinal anesthesia and sedation became a standard protocol for providing patients’ anxiolysis and amnesia at the intraoperative period. Propofol is the frequently used agent and combination regimens such as propofol vs alfentanil or midazolam vs fentanyl for sedation are commonly used in patients with chronic renal failure. The sedoanalgesia drug doses should be titrated and to reduce dose consumption combination regimens should be performed in hemodialysis patients.

Dexmedetomidine (DEX) is a selective α₂ receptor agonist agent, might be an alternative of choice for combination regimen with propofol due to its sedative and analgesic properties with minimal effects on ventilation. There are limited number of studies investigating the effect of DEX in patients with end stage renal disease (ESRD), however these studies are not specific to geriatric patients at the same time.

In this study we evaluate the effects of dexmedetomidine premedication on propofol consumption, sedation levels, hemodynamic changes, potential side effects in geriatric patients with ESRD who underwent hip fracture surgery under spinal anesthesia.

Materials and methods

This study was approved by the Baskent University Institutional Review Board and Ethics Committee (Project no: KA12/166). After obtaining written informed consent from the patients, 60 elderly patients (age ≥ 65 years) with end stage renal failure on dialysis treatment (glomerular filtration rate < 15, Stage 5) and hip fracture scheduled for antegrade femoral intramedulary nailing were included in this double-blind, randomized, controlled study. Exclusion criteria were decompensated respiratory or heart failure, liver failure, obesity (body mass index > 30), mental disorders, cognitive disorders, language problems, patients with a contraindication for regional anesthesia (coagulopathy, history of anticoagulant use, spinal cord disease and patients...
who rejected spinal anesthesia) and history of allergy to any medications used in this study.

The randomization scheme was developed by a computer and covered in sealed envelopes. These envelopes were prepared by an independent anesthesiologist who was not associated with the study. The envelopes were opened by the anesthesia technician, who also prepared the study drugs.

Patients were randomly divided into two groups:

**Group control (Group C):** Saline infusion for premedication, midazolam 0.02 mg/kg; spinal block (hyperbaric bupivacaine 0.5%, 12.5 mg, n = 30).

**Group DEX (Group D):** 0.5 µg/kg/10 min dexmedetomidine infusion for premedication, midazolam 0.02 mg/kg; spinal block (hyperbaric bupivacaine 0.5%, 12.5 mg, n = 30).

The study drugs were brought to the operation theater by the anesthesia technician. The anesthesiologist who performed premedications, spinal anesthesia, intraoperative postoperative follow-ups and data recordings was also blinded to the study drugs and group allocation.

A peripheral intravenous line was placed using an 18–20 gauge catheter in patients. Patients arrived in the operation theater without premedication. Routine anesthesia monitoring was performed with pulse-oxytometer, 5-lead ECG, noninvasive blood pressure measurement, pulse oxymetry and BIS. BIS scores were measured using an Aspect BIS Vista Monitor (Aspect Medical Systems, Inc). Electroencefalogram (EEG) was recorded using BIS QUATRO™ sensor stuck to the prepared forehead skin as explained in the instructions. All the patients received 0.02 mg/kg midazolam. 0.5 µg/kg DEX in 20 mL was administered in 10 min with an infusion pump. An equivalent volume of saline solution was given to the control group by using the same method. Baseline, 1-, 5-, 10-minute OAA/S scores, BIS, peripheral oxygen saturation (SpO₂), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP) values were recorded. At this period 250 mL of 0.9% NaCl was infused. Basal SBP, DBP, HR, SpO₂, BIS values were recorded before induction of the spinal block. Lumbar puncture was performed in lateral decubitus position with a Quincke® 27 gauge spinal needle at the L3-L4 interspaces using the midline approach. Patients were promptly rotated to supine position after block induction. Induction of the spinal block was accepted as time of 0 for all intraoperative data recordings. All parameters were recorded at 1-, 5-min and every 5 min for the first hour and following the first hour every 15 min during surgery.

Hypotension was described as ≥25% decrease in SBP from the baseline or in cases when systolic blood pressure decreases below 90 mmHg. Ephedrine 5 mg was administered intravenously and the rate of crystalloid infusion was increased.

The sensorial block level and the motor block level were assessed by pinprick test and modified Bromage scale (0 = no motor block, 1 = hip flexion with extended leg blocked, 2 = knee flexion blocked, 3 = complete motor block), respectively. Time to reach the level of T10 and to Bromage 3 was also noted. Propofol infusion was started in all the patients at a dose of 50 mcg/kg/min after the level of block raised to T10 dermatome level. OAA/S scale was used for evaluating the level of sedation16 (Table 1). Intermittent 0.5 mL bolus doses of propofol were given for reaching to target OAA/S scores and BIS levels at the beginning of the sedation if necessary. Sedative agent (DEX vs propofol) infusion starting time was accepted as 0 point for the recording of the time to reach to OAA/S score 4 and the time to reach to BIS ≤ 80. Target BIS values were between 70 and 80. Infusion rate was titrated according to the targeted OAA/S scores and BIS levels. In case OAA/S score < 4 and BIS < 70, propofol infusion rate was reduced. Propofol infusion was stopped at the beginning of skin suturing.

Patients were monitored at the postoperative care unit and all monitoring parameters were registered at every 5 min for 1 h. Criteria for transferring the ward were OAA/S = 5, BIS > 90, Bromage = 0–1.

Total propofol consumption, time necessary to reach the targeted level of sedation (OAA/S score 4 and BIS ≤ 80), propofol dose required for targeted OAA/S score and BIS levels, recovery time (BIS > 90), duration of surgery, amount of bleeding, vasoactive drug need were recorded. Possible side effects and possible complications during the preoperative, intraoperative period and the postoperative follow-up such as hypotension (SBP < 90 mmHg), bradycardia (HR < 60 min), respiratory depression (SpO₂ ≤ 90%), nausea, vomiting, and deep sedation were carefully monitored and recorded.

---

<table>
<thead>
<tr>
<th>Table 1</th>
<th>The observer’s assessment of alertness/sedation score.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Responsiveness</strong></td>
<td><strong>Speech</strong></td>
</tr>
<tr>
<td>Responds readily to name spoken in normal tone</td>
<td>Normal</td>
</tr>
<tr>
<td>Lethargic response to name spoken in normal tone</td>
<td>Mild slowing or thickening</td>
</tr>
<tr>
<td>Responds only after name is called loudly/or repeatedly</td>
<td>Slurring or prominent slowing</td>
</tr>
<tr>
<td>Responds only after mild prodding or shaking</td>
<td>Few recognizable words</td>
</tr>
<tr>
<td>Does not respond to mild prodding or shaking</td>
<td>–</td>
</tr>
</tbody>
</table>
Statistical analysis

Statistical analysis was performed using the statistical package SPSS (Version 17.0, SPSS Inc., Chicago, IL, USA). The primary outcome of this study was total propofol consumption during the hip fracture surgery. A power analysis indicated that 26 patients per group were required to detect a true difference of 40 mg between groups where the anticipated standard deviation was 43.16. The standard deviation was based on a pilot group of patients undergoing hip fracture surgery. The type I error was set at 0.05 and type II error at 0.10. We allowed for 4 more patients in each group to compensate for drop outs during the study period. For each continuous variable, normality was checked by Kolmogorov–Smirnov and Shapiro–Wilk tests and by histograms. Independent samples t-test and the Mann–Whitney U-test were performed for between-groups comparisons where appropriate. Pre-post measures were analyzed by Repeated Measure Analyses. Values of p < 0.05 were considered to be statistically significant.

Results

Sixty-hemodialysis dependent chronic renal failure patient scheduled for hip fracture repair were enrolled in the study. Fig. 1 presents the allocation of patients in groups. The groups were comparable with respect to demographic data, duration of surgery, time to reach to T10, to Bromage 3 and to Bromage 0 (Table 2).

Total propofol consumption, propofol dose required for targeted sedation levels and recovery time were significantly lower in Group D when compared with Group C (p < 0.001). The time to achieve to targeted sedation levels according to OAA/S score and BIS levels was significantly lower in Group C compared with Group D (p < 0.001). All the patients in Group D achieved targeted sedation levels with only DEX infusion without propofol infusion requirement (Table 3).

Comparison of preoperative OAA/S and BIS scores showed that the scores were significantly lower in Group D compared with Group C at preoperative 5th and 10th minutes (p < 0.001). Intraoperative OAA/S scores at 1-, 3-, 5-, 10th minutes and intraoperative BIS scores at 1-, 3-, 5-, 10-, 15th minutes were significantly lower in Group D compared with Group C (p < 0.05). The scores were similar in both groups till 75th minutes and were significantly lower at 75th, 90th minutes in group C (p < 0.05) (Figs. 2 and 3). Postoperative

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Demographic data and block characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group C</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>71.70 ± 4.84</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>163.73 ± 5.89</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>64.76 ± 7.02</td>
</tr>
<tr>
<td>Duration of surgery (min)</td>
<td>103.63 ± 7.77</td>
</tr>
<tr>
<td>Time to reach to T10 (min)</td>
<td>3.63 ± 0.55</td>
</tr>
<tr>
<td>Time to reach to Bromage 3 (min)</td>
<td>4.63 ± 0.56</td>
</tr>
<tr>
<td>Time to reach to Bromage 0 (min)</td>
<td>180.0 ± 8.51</td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD.
OAA/S scores were similar between groups (Fig. 3). Postoperative BIS scores were significantly lower at 5-, 10th minutes in Group C (p < 0.001); but was similar between groups after the 10th minutes (Fig. 2).

The heart rate, SBP, DBP, SpO2 showed decrease at Group D but there were no significant differences among two groups. Hypotension was observed at 8 patients in Group D and 9 patients in Group C; bradycardia observed at 6 patients in Group D and 5 patients in Group C during the intraoperative period. However the difference between the groups was not statistically significant. None of the patients exhibited respiratory depression, nausea and vomiting.

Discussion
In this study we showed that in geriatric patients with chronic renal failure sedation regimen with DEX premedication reduces total propofol consumption with rapid recovery time (Group C: 16.73 ± 1.84 min; Group D: 7.30 ± 1.52 min). On the other hand, according to the pharmacokinetic properties the time required to attain the aimed level of sedation was significantly shorter with propofol in the control group (5.08 ± 0.51 min) in comparison with the DEX premedication (7.65 ± 1.49 min).

Propofol is an ultrafast agent with a peak effect within 5 min of administration and is used for sedation or anesthesia maintenance.17,18 It has been reported that the pharmacokinetics of bolus or infusion doses are not affected markedly and can be used safely in ESRD patients.19,20 DEX is a highly selective α2 adrenoceptor agonist drug with sedative, sympatholytic, and analgesic actions. It is metabolized into its inactive metabolites in liver and its elimination is unaffected by renal disease. By virtue of these properties, it may offer an alternative option for sedation in ESRD patients.19,21 It has also been reported that it does not exert any respiratory depressant effect even in high doses, and it can be safely used for sedation in very elderly people.22

Dose determination studies for DEX in patients with chronic renal failure have demonstrated that the drug provided sufficient sedation with any significant side effect at a dose of 0.6 μg/kg/10 min in volunteer patients aged 18 to 65 years with creatinine clearance of <30.13 We also

Figure 2  BIS values of the patients. Values given are median (*p < 0.001; †p = 0.001; ‡p = 0.002).

Figure 3  OAA/S scores of the patients. Values given are median (*p < 0.001; †p = 0.001). PRE, preoperative; Io, intraoperative; PO, postoperative.

Table 3  Sedation data.

<table>
<thead>
<tr>
<th></th>
<th>Group C</th>
<th>Group D</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to achieve BIS ≤ 80 (min)</td>
<td>5.08 ± 0.51</td>
<td>7.65 ± 1.49</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time to reach to OAA/S score 4 (min)</td>
<td>4.03 ± 0.45</td>
<td>5.28 ± 0.85</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Propofol dose for BIS ≤ 80 (mg)</td>
<td>37.17 ± 5.83</td>
<td>0.00 ± 0.00</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total propofol consumption (mg)</td>
<td>197.0 ± 50.08</td>
<td>82.0 ± 23.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Recovery time (BIS &gt; 90) (min)</td>
<td>16.73 ± 1.84</td>
<td>7.30 ± 1.52</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD.
attained the desired sedation level without any significant hemodynamic response or side effect with similar premedication doses of DEX (0.5 μg/kg/10 min). Also we observed that all the patients in Group D reached targeted sedation levels following preoperative DEX infusion without any propofol requirement.

It has been reported that DEX used as an additive agent decreases propofol consumption.\textsuperscript{1,3} Also in our study a propofol dose titration was performed after DEX premedication for sedation with the guidance of OAA/S and BIS monitoring. It was demonstrated that propofol consumption was 2.4-fold greater than the study group (197.0 mg vs 82.0 mg) and thus the recovery period was 2.29 times longer in the control group (16.73 min vs 7.30 min). According to these results, it may be suggested that the lower OAA/S and BIS scores at 75 and 90 min at the intraoperative period as well as lower BIS scores and a significantly longer recovery time at 5 and 10 min at the postoperative period observed in the control group were associated with a higher propofol consumption, and thus dexmedetomidine had an important effect on postoperative early recovery.

One other parameter that should be taken into consideration is the hemodynamic response. In addition to sympathomimetic effects of spinal anesthesia, an additive interaction with cardiovascular effects of DEX and propofol may be possible. DEX is known to have some cardiovascular effects including hypotension and bradycardia owing to its sympathomimetic effects. However, it has been reported that it offers a good cardiovascular stability and thus it is a good sedative agent.\textsuperscript{4,5}

In a study comparing sedation application with dexmedetomidine or midazolam in ESRD patients it was reported that none of the patients experienced prolonged hypotension or bradycardia, all responded satisfactorily to the treatment, and none of them were excluded from the study even with large loading doses of 1 μg/kg/10 min of dex.\textsuperscript{14} We also did not demonstrate a significantly different hemodynamic response to DEX loaded at a dose of 0.5 μg/kg compared to the control group. However, both groups developed intraoperative hypotension (Group C, 30%; Group D, 26.7%) and bradycardia (Group C, 16.7%; Group D, 20%) after propofol infusion, which quickly resolved upon administration of sympathomimetics. This response may be an additive result of the venodilatative effect of propofol and the sympathomimetic effect of spinal anesthesia rather than the effect of DEX.

In the present study we found that premedication with DEX at a dose of 0.5 μg/kg for 10 min attained sufficient and aimed sedation levels without propofol requirement during the preoperative period. DEX premedication also reduced intraoperative propofol consumption, significantly promoted early recovery and was not the cause of severe side effects. In conclusion, we believe that low dose DEX premedication in addition to propofol infusion might be an alternative regimen in geriatric patients with ESRD for sedation.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgement

This study was supported by Baskent University Research Fund (Baskent University Institional Review Board and Ethics Committee, Project number KA 12/166).

Trial registration: Clinicaltrials.gov identifier NCT01837290.

References